Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439534 | 0.85 | HCRTR2 (0.35) | HCRTR2ALDH1A1MAPK1DRD2SIGMAR1 | |
| SCHEMBL21028701 | 0.84 | ALDH1A1 (0.32) | HCRTR2ALDH1A1MAPK1POLBHTT | |
| SCHEMBL469147 | 0.81 | CARM1 (0.47) | HRH1KCNH2ALDH1A1POLBHTT | |
| SCHEMBL25075207 | 0.80 | GNAI3 (0.38) | POLBHTTDRD2 | |
| SCHEMBL18173367 | 0.79 | HRH1 (0.35) | HRH1KCNH2SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL7884661 | 0.78 | KCNH2 (0.34) | HRH1KCNH2SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL26267339 | 0.76 | OPRM1 (0.34) | POLBHTTDRD2SIGMAR1 | |
| SCHEMBL26494066 | 0.76 | GNAO1 (0.44) | SIGMAR1 | |
| SCHEMBL4762635 | 0.76 | DRD2 (0.46) | DRD2 | |
| SCHEMBL13437776 | 0.75 | SMN1; SMN2 (0.43) | HRH1KCNH2SMN1; SMN2ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-01-08 | — | — | US | disclosed |
| US-8822500-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | HRH1 580/4885KCNH2 4411/4885HCRTR2 2956/4885 |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | HRH1 3502/4885KCNH2 4373/4885HCRTR2 4603/4885 |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | HRH1 580/4885KCNH2 4411/4885HCRTR2 2956/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | HRH1 580/4885KCNH2 4411/4885HCRTR2 2956/4885 |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | HRH1 2644/4885KCNH2 3058/4885HCRTR2 3950/4885 |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | HRH1 3502/4885KCNH2 4373/4885HCRTR2 4603/4885 |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | HRH1 2644/4885KCNH2 3058/4885HCRTR2 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.